Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 1,200 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 1,200 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This trade represents a 2.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jazz Pharmaceuticals Trading Down 2.4%

Shares of JAZZ stock opened at $230.56 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The firm has a market cap of $14.48 billion, a PE ratio of -11,522.24, a price-to-earnings-growth ratio of 0.21 and a beta of 0.32. The company has a 50-day moving average of $217.61 and a two-hundred day moving average of $188.84. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, analysts predict that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Negative Sentiment: Jazz Pharmaceuticals said the Phase 3 LAGOON trial for Zepzelca did not meet its primary endpoint of overall survival in second-line small cell lung cancer. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
• Negative Sentiment: Reuters reported the trial failure could put Zepzelca’s current regulatory status at risk, raising uncertainty around a key oncology asset. Jazz Pharmaceuticals lung cancer drug fails main trial goal
• Negative Sentiment: Industry coverage from multiple outlets reinforced the setback, suggesting investor concern may persist until Jazz clarifies next steps for Zepzelca. Jazz Pharma announces late-stage trial setback for lung cancer therapy
• Negative Sentiment: FiercePharma noted the latest twist in the Zepzelca saga, highlighting the importance of the drug to Jazz’s cancer franchise and the market’s negative reaction to the failure. In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
• Negative Sentiment: Separately, an SEC filing showed EVP Neena M. Patil sold 1,200 shares earlier this week, a small insider sale that may add to cautious sentiment. Jazz Pharmaceuticals PLC EVP Neena M. Patil sold shares
• Neutral Sentiment: Some recent commentary still frames Jazz as a value stock with a “moderate buy” analyst consensus, but this is being overshadowed by the trial disappointment. Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in JAZZ. Vestal Point Capital LP acquired a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $127,344,000. Goldentree Asset Management LP acquired a new stake in Jazz Pharmaceuticals during the third quarter worth approximately $149,597,000. Franklin Resources Inc. raised its holdings in Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after purchasing an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Jazz Pharmaceuticals by 160.2% during the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock worth $197,516,000 after purchasing an additional 715,361 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Jazz Pharmaceuticals by 258.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock worth $93,160,000 after purchasing an additional 395,000 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on JAZZ. Barclays raised their price objective on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. TD Cowen raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, May 26th. Finally, Leerink Partners raised their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $246.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.